Company intelligence / Profile preview

Efferon

Tuttlingen, Baden-Württemberg, Germanyefferon.com ↗

Ownership: Private
Development stage: Commercial

Overview

Efferon has developed and commercialized single-use therapeutic devices containing polymeric beads with LPS-selective ligands for the selective removal of bacterial endotoxins and cytokines from the bloodstream. These devices are used as part of integrated therapy in sepsis, septic shock, and multiple organ failure. The company focuses on increasing production to meet medical demand. Clinical results or trial data are not specified in public sources.

Therapeutic areas: OtherInfectious Diseases
Modalities: DevicePolymeric adsorbent technology
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

Efferon LPS

Commercial

Indications: Sepsis, Septic shock, Multiple organ failure

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Efferon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Efferon.

Explore the full profile